United States Biotechnology & Medical Research

Atossa Therapeutics Inc (ATOS)

Track

Atossa Therapeutics Inc has recorded no insider trading transactions within the past ninety days. The most recent activity occurred on May 21, 2025, when CEO Steven C. Quay purchased shares. Historical data indicates a pattern of executive acquisitions, with the last recorded market movement involving leadership increasing their equity stakes.
Ticker: ATOS Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Atossa Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.3
QUAY STEVEN C President & CEO Executive Director
Transaction date
Purchase
Price
66.68
Quantity 97,632 -6.6%
Value US$1,994,578
3.1
Remmel H. Lawrence Non-Executive Director
Transaction date
Purchase
Price
97.24
Quantity 69,581 +45.9%
Value US$141,684
0.6
Finn Jonathan Non-Executive Director
Transaction date
Purchase
Price
456.15
Quantity 92,101 +2.9%
Value US$4,028,165
1.5
WEAVER GREGORY L Former EVP, CFO, & Director Executive Director
Transaction date
Sale
Price
0.65
Quantity 50,000 -99.9%
Value US$32,500
1.5
WEAVER GREGORY L EVP & CFO Executive Director
Transaction date
Purchase
Price
0.97
Quantity 50,000 +90909.1%
Value US$48,500
2.5
Guse Kyle CFO, Gen Counsel and Secretary
Transaction date
Purchase
Price
0.34
Quantity 1,400 +16.3%
Value US$471
Guse Kyle CFO, Gen Counsel and Secretary
Transaction date
Purchase
Price
0.34
Quantity 8,600 +inf%
Value US$2,898
Remmel H. Lawrence
Transaction date
Purchase
Price
0.63
Quantity 2,500 +399.4%
Value US$1,580
Remmel H. Lawrence Non-Executive Director
Transaction date
Purchase
Price
0.33
Quantity 1,500 +16.0%
Value US$495
Chen Shu-Chih Non-Executive Director Large shareholder
Transaction date
Purchase
Price
0.37
Quantity 15,000 +0.3%
Value US$5,550
QUAY STEVEN C President & CEO Executive Director Large shareholder
Transaction date
Purchase
Price
0.37
Quantity 15,000 +0.3%
Value US$5,550
Chen Shu-Chih Non-Executive Director Large shareholder
Transaction date
Purchase
Price
0.53
Quantity 15,000 +0.3%
Value US$7,950
QUAY STEVEN C President & CEO Executive Director Large shareholder
Transaction date
Purchase
Price
0.53
Quantity 15,000 +0.3%
Value US$7,950
3.3
Chen Shu-Chih Non-Executive Director Large shareholder
Transaction date
Purchase
Price
0.20
Quantity 50,000 +1.2%
Value US$10,000
QUAY STEVEN C President & CEO Executive Director Large shareholder
Transaction date
Purchase
Price
0.20
Quantity 50,000 +1.1%
Value US$10,000
Remmel H. Lawrence Non-Executive Director
Transaction date
Purchase
Price
1.30
Quantity 5,400 +135.0%
Value US$7,020
CROSS ALEXANDER D Non-Executive Director
Transaction date
Purchase
Price
5.49
Quantity 500 +0.6%
Value US$2,745
Remmel H. Lawrence Non-Executive Director
Transaction date
Purchase
Price
4.05
Quantity 2,000 +inf%
Value US$8,100
3.3
Remmel H. Lawrence Non-Executive Director
Transaction date
Purchase
Price
4.20
Quantity 1,600 +400.0%
Value US$6,720
3.3
Remmel H. Lawrence Non-Executive Director
Transaction date
Purchase
Price
4.10
Quantity 400 +inf%
Value US$1,640
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-05-22 2025-05-21 B Purchase
1.3
QUAY STEVEN C

President & CEO

Executive Director
97,632 -6.6%
66.68
US$1,994,578 		97,632 -6.6% 66.68 US$1,994,578
2025-03-28 2025-03-26 B Purchase
3.1
Remmel H. Lawrence
Non-Executive Director
69,581 +45.9%
97.24
US$141,684 		69,581 +45.9% 97.24 US$141,684
2024-04-11 2024-04-10 B Purchase
0.6
Finn Jonathan
Non-Executive Director
92,101 +2.9%
456.15
US$4,028,165 		92,101 +2.9% 456.15 US$4,028,165
2023-11-17 2023-11-15 S Sale
1.5
WEAVER GREGORY L

Former EVP, CFO, & Director

Executive Director
50,000 -99.9%
0.65
US$32,500 		50,000 -99.9% 0.65 US$32,500
2023-06-20 2023-06-20 B Purchase
1.5
WEAVER GREGORY L

EVP & CFO

Executive Director
50,000 +90909.1%
0.97
US$48,500 		50,000 +90909.1% 0.97 US$48,500
2017-11-16 2017-11-15 B Purchase
2.5
Guse Kyle

CFO, Gen Counsel and Secretary
1,400 +16.3%
0.34
US$471 		1,400 +16.3% 0.34 US$471
2017-11-16 2017-11-15 B Purchase Guse Kyle

CFO, Gen Counsel and Secretary
8,600 +inf%
0.34
US$2,898 		8,600 +inf% 0.34 US$2,898
2017-04-18 2017-04-17 B Purchase Remmel H. Lawrence
2,500 +399.4%
0.63
US$1,580 		2,500 +399.4% 0.63 US$1,580
2016-04-04 2016-04-01 B Purchase Remmel H. Lawrence Non-Executive Director
1,500 +16.0%
0.33
US$495 		1,500 +16.0% 0.33 US$495
2016-03-10 2016-03-09 B Purchase Chen Shu-Chih Non-Executive Director Large shareholder
15,000 +0.3%
0.37
US$5,550 		15,000 +0.3% 0.37 US$5,550
2016-03-10 2016-03-09 B Purchase QUAY STEVEN C

President & CEO

Executive Director Large shareholder
15,000 +0.3%
0.37
US$5,550 		15,000 +0.3% 0.37 US$5,550
2016-02-17 2016-02-16 B Purchase Chen Shu-Chih Non-Executive Director Large shareholder
15,000 +0.3%
0.53
US$7,950 		15,000 +0.3% 0.53 US$7,950
2016-02-17 2016-02-16 B Purchase QUAY STEVEN C

President & CEO

Executive Director Large shareholder
15,000 +0.3%
0.53
US$7,950 		15,000 +0.3% 0.53 US$7,950
2016-01-21 2016-01-19 B Purchase
3.3
Chen Shu-Chih
Non-Executive Director Large shareholder
50,000 +1.2%
0.20
US$10,000 		50,000 +1.2% 0.20 US$10,000
2016-01-21 2016-01-19 B Purchase QUAY STEVEN C

President & CEO

Executive Director Large shareholder
50,000 +1.1%
0.20
US$10,000 		50,000 +1.1% 0.20 US$10,000
2015-06-15 2015-06-12 B Purchase Remmel H. Lawrence Non-Executive Director
5,400 +135.0%
1.30
US$7,020 		5,400 +135.0% 1.30 US$7,020
2013-06-27 2013-05-15 B Purchase CROSS ALEXANDER D Non-Executive Director
500 +0.6%
5.49
US$2,745 		500 +0.6% 5.49 US$2,745
2013-01-09 2013-01-08 B Purchase Remmel H. Lawrence Non-Executive Director
2,000 +inf%
4.05
US$8,100 		2,000 +inf% 4.05 US$8,100
2013-01-09 2013-01-08 B Purchase
3.3
Remmel H. Lawrence
Non-Executive Director
1,600 +400.0%
4.20
US$6,720 		1,600 +400.0% 4.20 US$6,720
2013-01-09 2013-01-08 B Purchase
3.3
Remmel H. Lawrence
Non-Executive Director
400 +inf%
4.10
US$1,640 		400 +inf% 4.10 US$1,640
Explore more

More insider trading research around Atossa Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America